Hospira Investors Go After Board Over Inflated Stock Prices

Law360, New York (December 22, 2011, 7:31 PM EST) -- A Hospira Inc. shareholder sued members of the drugmaker's board of directors Wednesday in Illinois federal court, accusing them of failing in their duties to the company, leading to manufacturing problems and regulatory probes, and artificially inflating stock prices by withholding this damaging information.

Shareholder Robert J. Casey II says Hospira executives, including Chairman of the Board Christopher Begley and CEO F. Michael Ball, failed to manage the company properly, causing production breakdowns and manufacturing deficiencies that will take three years and hundreds of millions of...
To view the full article, register now.